NCNANuCana plc
1.520USD-0.65%Mkt Cap: 6.33M $P/E: 0.023d ago
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy a…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap6.33M $
Enterprise Value-12.38M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-29.35M $
Revenue/Share—
Last Price1.520 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.02
P/E (Forward)-0.16
PEG—
EV/EBITDA0.86
EV/Revenue—
P/S—
P/B0.21
EPS (TTM)67.74
EPS (Forward)-9.43
52W Range
1.50040% of range1.550
52W High1.550 USD
52W Low1.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-120.66%
ROA-98.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.47M $
CapEx (TTM)193.00K $
FCF Margin—
FCF Yield-14.30%
Net Debt-18.83M $
Net Debt/EBITDA1.31
Balance Sheet
Debt/Equity0.03
Current Ratio4.73
Quick Ratio4.56
Book Value/Sh7.215 USD
Cash/Share4.686 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:200
Split DateAug 11, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.16M
Float4.16M
Insiders0.00%
Institutions2.60%
Short Interest
Short Ratio2.6d
Short % Float3.51%
Short % Out.3.51%
Shares Short146.28K
Short (prev mo.)115.77K
Technical
SMA 501.494 (+1.8%)
SMA 2002.376 (-36.0%)
Beta—
S&P 52W Chg21.00%
Avg Vol (30d)17.90K
Avg Vol (10d)48.13K
Technical Indicators
RSI (14)55.7
MACD0.0287
MACD Signal0.0049
MACD Hist.+0.0238
BB Upper1.639 USD
BB Middle1.415 USD
BB Lower1.191 USD
BB Width31.72%
ATR (14)0.1082 USD
Vol Ratio (20d)0.55x